EUPRAXIA PHARMACEUTICALS INC.
EPRXNext catalyst
EP-104GI
Eosinophilic Esophagitis
Get an email about EPRX's next catalysts
Track EUPRAXIA PHARMACEUTICALS (EPRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
EPRX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.26 | FQ end Sep/2026 | Call: tbd
EP-104GI Phase 2 Est. Readout (RESOLVE)
Estimated primary completion for EP-104GI trial (NCT05608681) in Eosinophilic Esophagitis. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in EUPRAXIA PHARMACEUTICALS INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in EUPRAXIA PHARMACEUTICALS INC.'s (EPRX) pipeline across Phase 2. Its lead program is EP-104GI (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EUPRAXIA PHARMACEUTICALS INC.'s next FDA catalyst?→
EUPRAXIA PHARMACEUTICALS INC.'s (EPRX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EPRX biotech catalysts?→
Add EPRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EUPRAXIA PHARMACEUTICALS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.